Abstract: Provided herein are bioactive molecule conjugates, preparation methods and use thereof, particularly bioactive molecule conjugates (such as antibody-drug conjugates and small molecule drug conjugates) obtained by improved coupling of a drug and a targeting moiety, as well as their preparation method and use for the treatment of a disease associated with an abnormal cell activity.

Abstract: Provided is a new-type cis-replicon construct for efficiently expressing a target protein, which comprises an RNA polymerase coding unit and a target protein coding unit. The replicon construct can drive the replication of the target protein coding unit and reduce or avoid the replication and expression of the RNA polymerase, thereby effectively improving the expression of the target protein and reducing the expression of the non-target protein.

Abstract: An apparatus for in-situ etching monitoring in a plasma processing chamber includes a continuous wave broadband light source, an illumination system configured to illuminate an area on a substrate with an incident light beam being directed from the continuous wave broadband light source at normal incidence to the substrate, a collection system configured to collect a reflected light beam being reflected from the illuminated area on the substrate, and to direct the reflected light beam to a first light detector, and a controller. The controller is configured to determine a property of the substrate or structures formed thereupon based on a reference light beam and the reflected light beam, and control an etch process based on the determined property. The reference light beam is generated by the illumination system by splitting a portion of the incident light beam and directed to a second light detector.

Abstract: Various aspects of the present disclosure generally relate to wireless communication. In some aspects, a user equipment (UE) may determine that one or more threshold criteria are satisfied, wherein the one or more threshold criteria include at least one of a first value for an uplink grant rate, a second value for a buffer size, or a third value for a packet data convergence protocol discard rate, wherein the one or more threshold criteria relate to a network condition with less than a reference uplink throughput and greater than a reference downlink throughput. The UE may transmit information identifying one or more adjusted measurement values based at least in part on the determination of the one or more threshold criteria. Numerous other aspects are described.

Abstract: Disclosed is a chip-level resonant acousto-optic coupling solid-state wave gyroscope based on MEMS technology. A surface acoustic progressive wave mode sensitive structure and a micro-ring resonant cavity optical detection structure are combined in the gyroscope. Through acousto-optic effect, mechanical strain of the device crystal caused by wave vibration of a primary surface acoustic wave and a secondary surface acoustic wave caused by Coriolis force is converted into a variation in the refractive index of an optical waveguide etched on the device, so that the optical signal transmitted in the waveguide diffracts, thereby generating frequency modulation. Meanwhile, a micro-ring resonant cavity using the resonance principle peels off the frequency change introduced by the primary surface acoustic wave, and obtains an output signal containing external angular velocity information.

Abstract: The disclosure relates to a bioactive molecule conjugate, preparation methods and use thereof, particularly relates to a novel bioactive molecule conjugate obtained by improving coupling of the drug and the targeting moiety in an ADC or SMDC, as well as its preparation method and use in the manufacture of a medicament for the treatment of a disease associated with an abnormal cell activity.

Abstract: Related is an anti-CLDN 18.2 antibody-drug conjugate, preparation method and use thereof. The antibody-drug conjugate and the composition thereof is capable of effectively binding CLDN 18.2 and inhibiting the growth of Claudin 18.2 positive tumors. Further related is a pharmaceutical composition comprising the antibody-drug conjugate or the composition, and use of the pharmaceutical composition in the preparation of a medicament for preventing and/or treating tumors.

Abstract: The present invention relates to an aryl amide compound of formula (I?), a pharmaceutical composition comprising same, a preparation method therefor, and the use thereof for preventing or treating tumor-related diseases or conditions.

Abstract: The present invention relates to a pyrazole compound and a preparation method therefor and a use thereof. In particular, the present invention relates to a compound shown in Formula I, a pharmaceutical composition containing same or a pharmaceutically acceptable form thereof, a pharmaceutical composition thereof, a preparation method therefor, and a use thereof.

Abstract: Provided are a salt and a crystal form of a pyrimidine compound, and preparation methods therefor. Specifically, provided are a salt and a crystal form of a compound I, including a crystal form of the salt, and preparation methods therefor.

Abstract: The present invention belongs to the field of pharmaceutical chemistry, and relates to a substituted pyrazine compound, a pharmaceutical composition comprising same, and the use thereof. In particular, the present invention relates to a compound with the structure of formula (I), which exhibits a good SHP2 inhibiting activity, and can act as an efficient SHP2 inhibitor for preventing and/or treating SHP2-related diseases.

Abstract: The present application relates to the field of superalloy, disclosing a method for internal stress regulation in superalloy disk forgings by pre-spinning. The method includes: Step S1, determining a target revolution for regulating internal stress in the disk forgings, and determining a target deformation magnitude of plastic deformation required for regulating the internal stress by the pre-spinning of the disk forgings; and Step S2, performing the pre-spinning of the disk forgings by the target revolution, monitoring a deformation magnitude of the disk forgings, and stopping the pre-spinning when a monitored deformation magnitude of the disk forgings reaches the target deformation magnitude.

Abstract: Disclosed are a solid form of (E)-3-((R)-4-(((R)-6-(2-chloro-4-fluorophenyl)-5-(methoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)morpholin-2-yl)acrylic acid, a preparation method therefor, a pharmaceutical composition comprising same, and the use thereof in the preparation of drugs for preventing or treating viral diseases.

Abstract: The present application relates to a solid form of a compound of Formula (I), a method for preparing the solid form, a pharmaceutical composition comprising the solid form, and uses of the solid form in preparing a medicament for treating or preventing peroxisome proliferator-activated receptor (PPAR)-related diseases such as nonalcoholic fatty liver disease (NAFLD).

Abstract: A compound represented by formula (I) or a pharmaceutically acceptable salt, a stereoisomer, a tautomer, a polymorph, a solvate, an N-oxide, an isotope labeled compound, a metabolite or a prodrug thereof, a pharmaceutical composition and a pill container comprising same, a preparation method therefor, and the use thereof in the preparation of drugs for preventing or treating STING-mediated related diseases.

Abstract: The present disclosure relates to a heterocyclic compound, a pharmaceutical composition comprising same, a preparation method therefor, and a use thereof. Specifically, the compound of the present invention is represented by formula (I), and used for preventing or treating a disease or condition related to RET activity.

Abstract: The invention provides a preparation method of a nickel-based wrought superalloy wheel disk forging used at high temperature, in which the alloy has high content of solution strengthening elements W, Mo and strengthening phase ?? phase forming elements Al, Ti, Nb and ?? phase content reaches 55-65%. In view of a series of technical problems caused by high ?? phase to alloy smelting and forging, the high-temperature stress relief annealing, low-temperature stress relief annealing process of steel ingot and high temperature homogenizing annealing of steel bar were proposed by optimizing the thermal process of wheel disk forging and controlling the precipitation and dissolution of ?? phase.

Abstract: Related is a nitrogen-containing benzoheterocycle compound containing a carboxylic acid group as shown in general formula (I), or a stereoisomer or pharmaceutically acceptable salt thereof. The compound has excellent pharmacokinetic properties and extremely remarkable liver targeting properties, and a pharmaceutical composition comprising the same may be used as a CCR antagonist, in particular a CCR2 and/or CCR5 antagonist and can be used in mediated disease, including, but not limited to, nonalcoholic fatty liver disease (NAFLD) or the like.

Abstract: A pharmaceutical composition comprising a 4?-thionucleoside phosphamide derivative or a pharmaceutically acceptable salt, ester, hydrate, solvate, and isomer thereof, any crystalline form thereof or racemate, metabolite, or a combination of a mixture thereof with other drugs, and a method and use thereof for disease treatment and/or prevention.

Abstract: The present invention relates to a nitrogen-containing fused ring compound, a preparation method and use thereof. Specifically, the present invention relates to a compound having the structure of Formula (X), a stereoisomer, tautomer or mixture thereof, a pharmaceutically acceptable salt, co-crystal, polymorph or solvate thereof, or a stable isotope derivative, metabolite or prodrug thereof. The compound of the invention may have the structure of Formula (I) or Formula (II). These compounds are useful for the treatment of an abnormal cell proliferation disease (e.g., cancer).